Lupin Launches Glucagon for Injection USP, 1mg/Vial in the United States

Global pharma major Lupin Limited has announced the launch of Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the United States. The product is bioequivalent to Glucagon for Injection, 1 mg/vial of Eli Lilly and Company. It is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations. The estimated annual sale of this product in the U.S. is USD 122 million (IQVIA MAT June 2025). Lupin Limited, headquartered in Mumbai, India, is a global pharmaceutical leader with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.